RxDoctor Payments Data

Justin Smith, APRN

Nurse Practitioner · Charleston, WVNPI 1225716376

Payments from drug & device makers

$962in general payments, 2019–2025

Across 58 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234
  • AstraZeneca$142
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$112
  • Bayer$98
  • Amgen$72
  • Exact Sciences$65
  • plus $238 from 8 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$962 in reported general payments places this provider in the 80th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$34,753
Medicare patients
178
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$53,559
OzempicSemaglutide42$52,143
FarxigaDapagliflozin Propanediol41$34,586
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$32,974
MounjaroTirzepatide26$31,068
EliquisApixaban32$30,410
XareltoRivaroxaban16$17,765
EntrestoSacubitril/Valsartan20$16,257
LinzessLinaclotide11$14,288
MyrbetriqMirabegron18$13,900
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,323
Tresiba Flextouch U-200Insulin Degludec11$12,547
TradjentaLinagliptin16$9,103
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,971
Novolog FlexpenInsulin Aspart23$6,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$52,14342 claims
AstraZenecaFarxiga$142$34,58641 claims
GSKTrelegy Ellipta$19$32,97436 claims
Lilly USA, LLCMounjaro$42$31,06826 claims
AbbVieLinzess, Synthroid$234$16,47535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →